August 16, 2021
News | QuaCell Biotechnology announced that it had completed nearly 200 million yuan of round B financing
Recently, Quacell Biotechnology Co., Ltd. announced the completion of nearly 200 million yuan of round B financing. This round of investment will be used to strengthen product R & D, improve technological innovation and production capacity as well as high-standard industrial order delivery capacity.
June 25, 2021
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
June 25, 2021 / Quacell Newsroom /- Dr. Poon, CEO of Quacell Biotechnology Co., Ltd. was invited by Re: Gen Open to be selected as Associate Editor.
April 30, 2021
China Medical System company(CMS) visited Quacell Biotechnology
Mr Lin Gang, Chairman of the Board of Directors of CMS Co., Ltd., Mr Wang Gang, General Manager of CMS Health Fund, and Mr Zhou Haiyang, Deputy General Manager, visited QuaCell Biotechnology Co., Ltd. (Quacell Biotechnology) and for investigation.
March 9, 2021
OBiO and QuaCell Biotechnology reached a strategic cooperation on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines
On March 9, 2021, OBiO and QuaCell Biotechnology jointly announced a strategic cooperation intent on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines. This cooperation aims to complement each other's technological advantages, connect upstream and downstream, and provide more comprehensive, high-quality and efficient technical services and solutions to cell and gene therapy customers around the world.